Literature DB >> 14705770

Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.

J F Chiou1, J A Liang, W H Hsu, J J Wang, S T Ho, A Kao.   

Abstract

Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP). Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to detect Pgp and LPR expressions in 40 patients with advanced NSCLC before Taxol-based chemotherapy. The chemotherapy response was evaluated by clinical and radiological methods in the third month after completion of treatment. No significant differences of prognostic factors (age, sex, body weight loss, performance status, tumor size, tumor stage, and tumor cell type) were found between the 20 patients with good and the 20 patients with poor responses. The incidence difference of positive Pgp expressions between good and poor responses was significant, however, the difference of LRP expression was not. We concluded that Taxol-based chemotherapy response of patients with NSCLC was related to Pgp but not LPR expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14705770     DOI: 10.1007/s00408-003-1029-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  19 in total

Review 1.  MDR1 gene expression in solid tumours.

Authors:  L J Goldstein
Journal:  Eur J Cancer       Date:  1996-06       Impact factor: 9.162

2.  Taxol: mechanisms of action and resistance.

Authors:  S B Horwitz; L Lothstein; J J Manfredi; W Mellado; J Parness; S N Roy; P B Schiff; L Sorbara; R Zeheb
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.

Authors:  C H Kao; J F Hsieh; S C Tsai; Y J Ho; S P Changlai; J K Lee
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

5.  Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution.

Authors:  S H Cheng; W Lam; A S Lee; K P Fung; R S Wu; W F Fong
Journal:  Toxicol Appl Pharmacol       Date:  2000-04-15       Impact factor: 4.219

6.  Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer.

Authors:  Y C Shiau; S C Tsai; J J Wang; Y J Ho; S T Ho; C H Kao
Journal:  Lung       Date:  2001       Impact factor: 2.584

7.  Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.

Authors:  M Kitazono; T Sumizawa; Y Takebayashi; Z S Chen; T Furukawa; S Nagayama; A Tani; S Takao; T Aikou; S Akiyama
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

Review 8.  Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

Authors:  P A Francis; M G Kris; J R Rigas; S C Grant; V A Miller
Journal:  Lung Cancer       Date:  1995-04       Impact factor: 5.705

9.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

10.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

Authors:  M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper
Journal:  Int J Cancer       Date:  1996-01-17       Impact factor: 7.396

View more
  23 in total

1.  Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.

Authors:  Aleem Gangjee; Ying Zhao; Lu Lin; Sudhir Raghavan; Elizabeth G Roberts; April L Risinger; Ernest Hamel; Susan L Mooberry
Journal:  J Med Chem       Date:  2010-10-25       Impact factor: 7.446

Review 2.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

4.  ELR510444, a novel microtubule disruptor with multiple mechanisms of action.

Authors:  A L Risinger; C D Westbrook; A Encinas; M Mülbaier; C M Schultes; S Wawro; J D Lewis; B Janssen; F J Giles; S L Mooberry
Journal:  J Pharmacol Exp Ther       Date:  2010-12-09       Impact factor: 4.030

5.  Role of gambogic acid and NaI131 in A549/DDP cells.

Authors:  Jing Huang; Xiaoli Zhu; Huan Wang; Shuhua Han; Lu Liu; Yan Xie; Daozhen Chen; Qiang Zhang; Li Zhang; Yue Hu
Journal:  Oncol Lett       Date:  2016-11-25       Impact factor: 2.967

6.  Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy.

Authors:  Susan L Mooberry; Michael K Hilinski; Erin A Clark; Paul A Wender
Journal:  Mol Pharm       Date:  2008-07-29       Impact factor: 4.939

7.  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Authors:  Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2014-05-14       Impact factor: 3.641

8.  The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

Authors:  April L Risinger; Evelyn M Jackson; Lisa A Polin; Gregory L Helms; Desiree A LeBoeuf; Patrick A Joe; Elizabeth Hopper-Borge; Richard F Ludueña; Gary D Kruh; Susan L Mooberry
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 9.  Microtubule dynamics as a target in oncology.

Authors:  April L Risinger; Francis J Giles; Susan L Mooberry
Journal:  Cancer Treat Rev       Date:  2008-12-30       Impact factor: 12.111

Review 10.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.